Drug firm Glenmark gets USFDA nod for generic diabetes drug to market in US

Drug firm Glenmark said it has received approval from the US health regulator to market a generic medication to treat diabetes in the American market.

Glenmark
Glenmark Pharmaceuticals
Press Trust of India New Delhi
1 min read Last Updated : Feb 17 2023 | 12:55 PM IST

Drug firm Glenmark said it has received approval from the US health regulator to market a generic medication to treat diabetes in the American market.

Glenmark Pharmaceuticals Inc, USA, a unit of the company, has received tentative approval from the US Food & Drug Administration (US FDA) for Saxagliptin Tablets in strengths of 2.5 mg and 5 mg, the Mumbai-based drug maker said in a statement.

The company's product is the generic version of AstraZeneca AB's Onglyza tablets (2.5 mg and 5 mg), it added.

According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza tablets (2.5 mg and 5 mg) achieved annual sales of around USD 122.3 million.

Glenmark said its current portfolio consists of 179 products authorised for distribution in the US marketplace.

The drug firm has 46 abbreviated new drug applications (ANDAs) pending approval with the USFDA, it added.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, it stated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :DiabetesUSFDADrug

First Published: Feb 17 2023 | 12:55 PM IST

Next Story